JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
Revenue
JW (Cayman) Therapeutics Co Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Revenue
¥173.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥9.6B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
¥6.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
266%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
¥49.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
65%
|
CAGR 10-Years
50%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Revenue
¥1.9B
|
CAGR 3-Years
51%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Revenue?
Revenue
173.9m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Revenue amounts to 173.9m CNY.
What is JW (Cayman) Therapeutics Co Ltd's Revenue growth rate?
Revenue CAGR 1Y
19%
Over the last year, the Revenue growth was 19%.